2.00
前日終値:
$2.10
開ける:
$2.2
24時間の取引高:
21,987
Relative Volume:
0.32
時価総額:
$5.74M
収益:
$32.96M
当期純損益:
$-4.23M
株価収益率:
-0.0129
EPS:
-155.3294
ネットキャッシュフロー:
$-14.00M
1週間 パフォーマンス:
-12.28%
1か月 パフォーマンス:
-11.50%
6か月 パフォーマンス:
-37.50%
1年 パフォーマンス:
-98.35%
Sunshine Biopharma Inc Stock (SBFM) Company Profile
名前
Sunshine Biopharma Inc
セクター
電話
954-515-0810
住所
333 LAS OLAS WAY, FORT LAUDERDALE
SBFM を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
SBFM
Sunshine Biopharma Inc
|
2.00 | 5.74M | 32.96M | -4.23M | -14.00M | -155.33 |
![]()
ZTS
Zoetis Inc
|
163.11 | 73.07B | 9.26B | 2.49B | 2.30B | 5.47 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
15.05 | 47.43B | 30.25B | 1.37B | 5.08B | 0.4257 |
![]()
HLN
Haleon Plc Adr
|
10.24 | 45.72B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.08 | 17.28B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
ITCI
Intra Cellular Therapies Inc
|
131.81 | 14.03B | 612.78M | -86.37M | -62.91M | -0.87 |
Sunshine Biopharma Inc (SBFM) 最新ニュース
Sunshine Biopharma Inc expected to post earnings of 11 cents a shareEarnings Preview - TradingView
Sunshine Biopharma signs agreement for rights to market two generic antibiotics - Yahoo Finance
Sunshine Biopharma to market new antibiotics in Canada By Investing.com - Investing.com Australia
Sunshine Biopharma acquires marketing rights for two new antibiotics in Canada - MSN
Sunshine Biopharma to market new antibiotics in Canada - Investing.com India
Major Antibiotics Deal: Sunshine Biopharma Expands Portfolio in Billion-Dollar Market - StockTitan
Sunshine Biopharma stock hits 52-week low at $2.01 By Investing.com - Investing.com Australia
Sunshine Biopharma stock hits 52-week low at $2.01 - Investing.com India
Sunshine Biopharma (NASDAQ:SBFMW) Trading Down 0.5% – Should You Sell? - Defense World
Sunshine Biopharma expands with new gastrointestinal drug By Investing.com - Investing.com Canada
Sunshine Biopharma expands with new gastrointestinal drug - Investing.com India
Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market - ACCESS Newswire
Sunshine Biopharma stock hits 52-week low at $2.09 By Investing.com - Investing.com Australia
Sunshine Biopharma stock hits 52-week low at $2.09 - Investing.com India
A Look at Sunshine Biopharma Inc (SBFM) Shares in the Recent Past Indicates Growth - SETE News
Sunshine Biopharma (NASDAQ:SBFMW) Trading 30% Higher – Should You Buy? - Defense World
Sunshine Biopharma Announces Reverse Stock Split - ACCESS Newswire
Sunshine Biopharma Launches Two New Generic Prescription Drugs - ACCESS Newswire
Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R) - ACCESS Newswire
Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54% - ACCESS Newswire
Sunshine Biopharma (NASDAQ:SBFM) Stock Quotes, Forecast and News Summary - Benzinga
Who’s Hired? Haruvi Returns For A Second Term As AAM Chair - News & Insights
Sunshine Biopharma launches Olanzapine and Olanzapine ODT - Indian Pharma Post
Sunshine Biopharma introduces new generic drugs in Canada - MSN
Sunshine Biopharma Appoints New Chief Commercial Officer - MSN
Sunshine Biopharma Launches Generic Mental Health Drug in Rapidly Growing Canadian Market - StockTitan
Sunshine Biopharma Appoints Michel Roy as Chief Commercial Officer - Defense World
Sunshine Biopharma appoints Michel Roy as CCO - MSN
Sunshine Biopharma names new Chief Commercial Officer By Investing.com - Investing.com South Africa
Sunshine Biopharma names new Chief Commercial Officer - Investing.com
Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer - WICZ
Sunshine Biopharma, Inc. (NASDAQ:SBFM) Short Interest Down 14.6% in December - Defense World
Sunshine Biopharma Inc. Elects New Directors and Ratifies Appointment of Independent Registered Public Accounting Firm - Defense World
Sunshine Biopharma re-elects board, ratifies CPA firm By Investing.com - Investing.com Nigeria
Sunshine Biopharma re-elects board, ratifies CPA firm - Investing.com India
Sunshine Biopharma’s PLpro inhibitor shows activity in SARS-CoV-2 - BioWorld Online
Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus - AccessWire
Sunshine Biopharma's Novel COVID-19 Oral Treatment Shows Breakthrough Antiviral Activity in Preclinical Study - StockTitan
Sunshine Biopharma Launches a New Generic Prescription Drug - AccessWire
Sunshine Biopharma Launches Generic Allergy Drug in $1.3B Global Bilastine Market - StockTitan
Mouse model studies provide proof of concept for Sunshine Biopharma’s K1.1 mRNA product for HCC - BioWorld Online
Sunshine Biopharma Announces Breakthrough Research Results on the Company’s K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma - AccessWire
Sunshine Biopharma's K1.1 mRNA Shows Breakthrough Results in Liver Cancer Treatment - StockTitan
SBFM (Sunshine Biopharma) Cash From Discontinued Investing Activities : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
SBFM (Sunshine Biopharma) Operating Income : $-4.91 Mil (TTM As of Sep. 2024) - GuruFocus.com
Sunshine Biopharma Inc (SBFM) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):